Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Liabilities and Shareholders Equity of $11.9 billion for Q1 2026, up 2.82% year-over-year from $11.5 billion in Q1 2025, and up 1.72% quarter-over-quarter from $11.7 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $11.9 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 2.82% year-over-year to $11.9 billion; the TTM figure through Mar 2026 stood at $45.8 billion (down 2.85% YoY), while the FY2025 annual figure was $11.7 billion, down 2.94% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $11.9 billion, up from $11.7 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $12.3 billion in Q3 2024, with the low at $10.4 billion in Q3 2022.
- The 5-year median for Liabilities and Shareholders Equity is $11.4 billion (2025), against an average of $11.4 billion.
- Peak annual rise in Liabilities and Shareholders Equity reached 74.19% in 2022, while the deepest fall reached 16.78% in 2022.
- Jazz Pharmaceuticals' Liabilities and Shareholders Equity stood at $10.8 billion in 2022, then grew by 5.15% to $11.4 billion in 2023, then gained by 5.43% to $12.0 billion in 2024, then declined by 2.94% to $11.7 billion in 2025, then climbed by 1.72% to $11.9 billion in 2026.
- Business Quant data shows JAZZ's Liabilities and Shareholders Equity at $11.9 billion in Q1 2026, $11.7 billion in Q4 2025, and $11.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 11.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.08 Bn |
| Mar 31, 2026 | 11.86 Bn |
| Dec 31, 2025 | 11.66 Bn |
| Sep 30, 2025 | 11.36 Bn |
| Jun 30, 2025 | 10.94 Bn |
| Mar 31, 2025 | 11.53 Bn |
| Dec 31, 2024 | 12.01 Bn |
| Sep 30, 2024 | 12.26 Bn |
| Jun 30, 2024 | 11.36 Bn |
| Mar 31, 2024 | 11.33 Bn |
| Dec 31, 2023 | 11.39 Bn |
| Sep 30, 2023 | 11.20 Bn |
| Jun 30, 2023 | 11.26 Bn |
| Mar 31, 2023 | 11.05 Bn |
| Dec 31, 2022 | 10.84 Bn |
| Sep 30, 2022 | 10.38 Bn |
| Jun 30, 2022 | 11.20 Bn |
| Mar 31, 2022 | 11.77 Bn |
| Dec 31, 2021 | 12.30 Bn |
| Sep 30, 2021 | 12.48 Bn |